R&D Industry Finds Biosimilar Interchangeability Statement By EU Regulators ‘Concerning’

 
• By Francesca Bruce

A joint statement from the European Medicines Agency and Heads of Medicines Agencies on biosimilar interchangeability is “concerning,” says Europe’s R&D-based industry federation, EFPIA.

Interchangeable
Biosimilars and reference products are interchangeable, say the EMA and HMA • Source: Shutterstock

More from Europe

More from Geography